Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer.

In the ARAT-alone group, there was a trend towards longer OS for those who received enzalutamide compared to abiraterone, though it did not reach statistical significance (Fig. 2 B).” Similarly, if chemotherapy was used after ARAT, there was no significant difference in survival between the two groups (Fig. 2 C).

also in 111,027 other papers